# OnCo record paper-i-spy-2-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-i-spy-2-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-i-spy-2-jama-oncol-2020" ;
  schema:name "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial"@en ;
  schema:description "Published report from the I-SPY 2 trial registered as NCT01042379, in JAMA Oncology (2020), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-i-spy-2-jama-oncol-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2019.6650>, <https://pubmed.ncbi.nlm.nih.gov/32053137/>, <https://europepmc.org/article/MED/32053137>, <https://clinicaltrials.gov/study/NCT01042379> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2019.6650> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Nanda R, Liu MC, Yau C, et al." ;
  onco:trials <https://onco.cc/trials/i-spy-2/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .